Contract 75N94022P00594
Genscript Probio USA Inc. · Department Of Health And Human Services · August 7, 2022
Genscript Probio USA Inc. was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on August 7, 2022 for an undisclosed amount of work in biological product (except diagnostic) manufacturing. Performance is in Piscataway, NJ. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 10, 2024.
Contract details
- PIID
- 75N94022P00594
- Award type
- Purchase Order
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Competed Under Sap
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Piscataway, NJ
- First action
- August 7, 2022
- Latest action
- July 10, 2024
Description
NICHD - ECONOMY GENE SYNTHESIS
Modification timeline
-
July 10, 2024Mod P00001$-14.7K
-
August 7, 2022Base award$14.7K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | Department Of Health And Human Services | March 31, 2026 | $20.6K |
| Georgia Tech Research Corp | Department Of Health And Human Services | March 28, 2026 | $145.8K |
| Seqirus Inc | Department Of Health And Human Services | March 25, 2026 | $23.7K |
| Seqirus Inc | Department Of Health And Human Services | March 24, 2026 | $0 |
| Battelle Memorial Institute | Department Of Health And Human Services | March 19, 2026 | $2.80M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 19, 2026 | $53.21M |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75N94022P00594?
Contract 75N94022P00594 is a federal contract awarded to Genscript Probio USA Inc. by Department Of Health And Human Services on August 7, 2022 for an undisclosed amount of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 1 time since the base award.
Who won contract 75N94022P00594?
Genscript Probio USA Inc. won contract 75N94022P00594 from Department Of Health And Human Services.
How much is contract 75N94022P00594 worth?
Contract 75N94022P00594 has no obligated funds in the available record. It may be a pre-award placeholder or an indefinite-delivery vehicle awaiting task orders.